Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement
Roche/GlaxoSmithKline's aggressive pricing strategy for Boniva injection relative to the oral formulation indicates the firms feel Medicare Part B is a more advantageous reimbursement environment than Part D
You may also be interested in...
Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward
Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said
Roche/GlaxoSmithKline's once-quarterly osteoporosis therapy Boniva injection does not present serious safety concerns compared with oral bisphosphonates, labeling for the I.V. formulation of the drug suggests